These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 25452139

  • 1. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA, Yang S, Kerwin E, Trivedi R, Edwards LD, Pascoe S.
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [Abstract] [Full Text] [Related]

  • 2. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [Abstract] [Full Text] [Related]

  • 4. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma.
    Lee LA, Briggs A, Edwards LD, Yang S, Pascoe S.
    Respir Med; 2015 Jan; 109(1):63-73. PubMed ID: 25464907
    [Abstract] [Full Text] [Related]

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H, Orozco S, Allen A.
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [Abstract] [Full Text] [Related]

  • 7. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
    Kerwin E, Pascoe S, Bailes Z, Nathan R, Bernstein D, Dahl R, von Maltzahn R, Robbins K, Fowler A, Lee L.
    Respir Res; 2020 Jun 12; 21(1):148. PubMed ID: 32532275
    [Abstract] [Full Text] [Related]

  • 8. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J, Kang J, Lee SH, Wang C, Zhou X, Crawford J, Jacques L, Stone S.
    Respir Med; 2015 Jan 12; 109(1):44-53. PubMed ID: 25524507
    [Abstract] [Full Text] [Related]

  • 9. Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma.
    Yang S, Goyal N, Beerahee M, Trivedi R, Lee L, Pascoe S.
    Eur J Clin Pharmacol; 2015 Sep 12; 71(9):1051-8. PubMed ID: 26174114
    [Abstract] [Full Text] [Related]

  • 10. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM.
    J Asthma; 2015 Sep 12; 52(10):1073-83. PubMed ID: 26291137
    [Abstract] [Full Text] [Related]

  • 11. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
    Boulet LP, Abbott C, Brusselle G, Edwards D, Oppenheimer J, Pavord ID, Pizzichini E, Sagara H, Slade D, Wechsler ME, Gibson PG.
    J Allergy Clin Immunol Pract; 2024 May 12; 12(5):1244-1253.e8. PubMed ID: 38309696
    [Abstract] [Full Text] [Related]

  • 12. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER, Lötvall J, O'Byrne PM, Woodcock A, Busse WW, Kerwin EM, Forth R, Medley HV, Nunn C, Jacques L, Bateman ED.
    J Allergy Clin Immunol Pract; 2014 May 12; 2(5):553-61. PubMed ID: 25213048
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y, Hozawa S, Sagara H, Ohbayashi H, Lee LA, Crawford J, Tamaoki J, Nishi T, Fowler A.
    Curr Med Res Opin; 2021 Sep 12; 37(9):1657-1665. PubMed ID: 34162298
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID.
    Lancet Respir Med; 2021 Jan 12; 9(1):69-84. PubMed ID: 32918892
    [Abstract] [Full Text] [Related]

  • 15. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 12; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 16. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D, Andersen L, Forth R, Jacques L, Yates L.
    J Asthma; 2018 Sep 12; 55(9):984-993. PubMed ID: 28961020
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
    Respir Med; 2013 Oct 12; 107(10):1538-46. PubMed ID: 23830094
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 12; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 19. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

  • 20. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.
    Thorax; 2012 Jan 29; 67(1):35-41. PubMed ID: 21828231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.